Zura Bio Limited (NASDAQ:ZURA) Director Sells $2,734,458.09 in Stock

Zura Bio Limited (NASDAQ:ZURA) Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Zura Bio Stock Down 0.3 %

Zura Bio stock opened at $3.00 on Friday. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $6.35. The firm’s fifty day moving average price is $4.09 and its 200 day moving average price is $4.02.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently modified their holdings of ZURA. AQR Capital Management LLC bought a new stake in shares of Zura Bio during the 2nd quarter valued at about $43,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Zura Bio during the 3rd quarter valued at about $46,000. Renaissance Technologies LLC grew its position in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Zura Bio during the 3rd quarter valued at about $62,000. Finally, Valence8 US LP bought a new stake in shares of Zura Bio during the 3rd quarter valued at about $71,000. Institutional investors own 61.14% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ZURA. Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock. Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Finally, Chardan Capital reduced their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.